Scientists demonstrated that the F-box protein FBXL2 was a critical negative regulator of breast cancer stem cell stemness and that downregulation of FBXL2 played a causal role in TNBC drug resistance.
[Oncogene]
Home Newsletters Mammary Cell News FBXL2 Promotes E47 Protein Instability to Inhibit Breast Cancer Stemness and Paclitaxel...
